Hepatitis B virus/human immunodeficiency virus coinfection: Interaction among human immunodeficiency virus infection, chronic hepatitis B virus infection, and host immunity

Chinese Medical Journal

Volumn 125, Issue 13, 2012, Pages 2371-2377

  Li, Yi jia ^a   Wang, Huan ling ^a   Li, Tai sheng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Hepatitis B virus; Human immunodeficiency virus; Immunity

Indexed keywords

CD14 ANTIGEN; CD38 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHLOROQUINE; CYCLOOXYGENASE 2 INHIBITOR; HEPATITIS B VIRUS X PROTEIN; HYDROXYCHLOROQUINE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADAPTIVE IMMUNITY; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LIVER CELL; LONG TERMINAL REPEAT; MIXED INFECTION; REGULATORY T LYMPHOCYTE; REVIEW; STELLATE CELL; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE;

EID: 84863798206     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.13.023     Document Type: Review

References (77)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: 21.
2. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49: S138-S145.
3. Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, Mutchaba G, et al. Impact of 3TC on HIV and HBV related outcomes in HIV/HBV individuals in a randomized clinical trial of antiretroviral therapy in South Africa. AIDS 2011; 29: 29.
4. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
5. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009; 49: 1268-1273.
6. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol 2010; 58: 258-266.
7. Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol 2011; 17: 1927-1938.
8. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008; 48: 743-746.
9. Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat 2010; 17: 1-15.
10. Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 2009; 81: 441-445.
11. Gupta S, Singh S. Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis 2010; 10: 53.
12. +T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol 2005; 79: 3038-3051.
13. Lascar RM, Lopes AR, Gilson RJ, Dunn C, Johnstone R, Copas A, et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J Infect Dis 2005; 191: 1169-1179.
14. Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol 2006; 44: 28.
15. +T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. J Virol 2010; 84: 2657-2665.
16. +T cell survival in HIV infection. J Exp Med 2006; 203: 2281-2292.
17. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215-4225.
18. Brandt L, Benfield T, Mens H, Clausen LN, Katzenstein TL, Fomsgaard A, et al. Low level of regulatory T cells and maintenance of balance between regulatory T cells and TH17 cells in HIV-1-infected elite controllers. J Acquir Immune Defic Syndr 2011; 57: 101-108.
19. +T regulatory cells correlates with progressive disease. J Virol 2011; 85: 1287-1297.
20. van den Berg R, van Hoogstraten I, van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev 2009; 11: 157-164.
21. del Pozo Balado Mdel M, Leal M, Mendez Lagares G, Mata RC, Lopez-Cortes LF, Viciana P, et al. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis 2010; 202: 362-369.
22. Cagigi A, Nilsson A, Pensieroso S, Chiodi F. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis 2010; 10: 499-503.
23. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197: 403-411.
24. Wilson CM, Ellenberg JH, Sawyer MK, Belzer M, Crowley-Nowick PA, Puga A, et al. Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. Reaching for excellence in adolescent care and health. J Adolesc Health 2001; 29: 123-129.
25. Altfeld M, Fadda L, Frleta D, Bhardwaj N. DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol 2011; 11: 176-186.
26. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2006; 85: 16-23.
27. Ford ES, Puronen CE, Sereti I. Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm. Curr Opin HIV AIDS 2009; 4: 206-214.
28. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.
29. +T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197: 126-133.
30. Sandler NA, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 2: 2.
31. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, et al. Human Immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135: 226-233.
32. Crane M, Rajasuriar R, Avihingsanon A, Matthews G, Skinner N, Tangkitvanich P, et al. LPS, immune activation and liver disease in HIV-HBV co-infection. 18th CROI Conference on Retroviruses and Opportunistic Infections, Boston, 2011.
33. Su GL, Klein RD, Aminlari A, Zhang HY, Steinstraesser L, Alarcon WH, et al. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology 2000; 31: 932-936.
34. Schnabl B, Brandl K, Fink M, Gross P, Taura K, Gabele E, et al. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun 2008; 375: 210-214.
35. Iser DM, Lewin SR. The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection. Antivir Ther 2009; 14: 155-164.
36. Martin CM, Welge JA, Blackard JT. Hepatitis B virus (HBV) X gene diversity and evidence of recombination in HBV/HIV co-infected persons. J Med Virol 2011; 22: 1142-1150.
37. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180: 607-613.
38. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48: 1062-1069.
39. Thio CL. Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy. Antivir Ther 2010; 15: 487-491.
40. Chen G, Yu T, Huang K, Chen Q. Antiviral therapy of decompensated hepatitis B virus-related cirrhosis. Chin Med J 2012; 125: 373-377.
41. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ. Mutations associated with lamivudineresistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol 2007; 79: 1650-1654.
42. Tuma P, Pineda JA, Labarga P, Vidal F, Rodriguez C, Poveda E, et al. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. Antivir Ther 2011; 16: 585-589.
43. Blackard JT, Sherman KE. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008; 15: 323-330.
44. Iser DM, Avihingsanon A, Wisedopas N, Thompson AJ, Boyd A, Matthews GV, et al. Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS 2011; 25: 197-205.
45. Hoffmann CJ, Seaberg EC, Young S, Witt MD, D'Acunto K, Phair J, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23: 1881-1889.
46. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601.
47. Omland LH, Weis N, Skinhøj P, Laursen AL, Christensen PB, Nielsen HI, et al. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study. HIV Medicine 2008; 9: 300-306.
48. Sheng WH, Chen MY, Hsieh SM, Hsiao CF, Wang JT, Hung CC, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004; 38: 1471-1477.
49. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18: 1169-1177.
50. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4: 241-249.
51. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009; 48: 1763-1771.
52. Qu W, Robinson M, Zhang FJ. Factors influencing the natural history of HIV-1 infection. Chin Med J 2008; 121: 2613-2621.
53. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
54. Fuping G, Wei L, Yang H, Zhifeng Q, Lingyan Z, Yanling L, et al. Impact of hepatitis C virus coinfection on HAART in HIV-infected individuals: multicentric observation cohort. J Acquir Immune Defic Syndr 2010; 54: 137-142.
55. Al-Harthi L, Voris J, Du W, Wright D, Nowicki M, Frederick T, et al. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis 2006; 193: 1202-1210.
56. Gomez-Gonzalo M, Carretero M, Rullas J, Lara-Pezzi E, Aramburu J, Berkhout B, et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem 2001; 276: 35435-35443.
57. Mu Y, Yu Y, Yue X, Musarat I, Gong R, Zhu C, et al. The X protein of HBV induces HIV-1 long terminal repeat transcription by enhancing the binding of C/EBPbeta and CREB1/2 regulatory proteins to the long terminal repeat of HIV-1. Virus Res 2011; 156: 81-90.
58. Cabrerizo M, Bartolome J, Caramelo C, Barril G, Carreno V. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000; 32: 116-123.
59. Lu L, Zhang HY, Yueng YH, Cheung KF, Luk JM, Wang FS, et al. Intracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patients. J Viral Hepat 2009; 16: 104-112.
60. +lymphocytes and viremia in treated hepatitis B patients. World J Gastroenterol 2011; 17: 2191-2198.
61. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790.
62. +cell count. AIDS 2011; 25: 1385-1394.
63. Lyons JL, Uno H, Ancuta P, Kamat A, Moore DJ, Singer EJ, et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr 2011; 57: 371-379.
64. Watanabe T, Bertoletti A, Tanoto TA. PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J Viral Hepat 2010; 17: 453-458.
65. Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HLA, van der Molen RG, et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009; 126: 280-289.
66. Chang JJ, Sirivichayakul S, Avihingsanon A, Thompson AJ, Revill P, Iser D, et al. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol 2009; 83: 7649-7658.
67. +T cells. J Exp Med 2005; 201: 2023-2033.
68. Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One 2011; 6: e15324.
69. Izquierdo-Useros N, Naranjo-Gomez M, Erkizia I, Puertas MC, Borras FE, Blanco J, et al. HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse? PLoS Pathog 2010; 6: e1000740.
70. Riordan SM, Skinner N, Kurtovic J, Locarnini S, Visvanathan K. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol 2006; 13: 972-974.
71. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007; 45: 102-110.
72. +T cells. Retrovirology 2009; 6: 42.
73. Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, ART-treated, immunological non-responders. Blood 2011; 118: 3263-3272.
74. Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010; 84: 12082-12086.
75. Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M, et al. An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol 2011; 85: 6557-6566.
76. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008; 45: 963-970.
77. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-354.